Kornimate/medical-research-clean huggingface dataset:
study of cardiorespiratory arrests that occurred in the surgical block and adjacent places

Conditions: Cardiorespiratory Arrest

Summary: a protocol for recording cardiopulmonary arrest (crp) data in the in-hospital surgical block has been designed with the utstein template model. the database is hosted in accordance with european legislation on patient data protection. invitation to participate will be sent to spanish hospitals in the first phase. once this is over, participation in the registry will be opened to european hospitals. survival and neurological outcome will be evaluated upon discharge from the surgical block. the study design is a prospective observational registry of a cohort of subjects who have suffered a crp in the surgical block.

patients will be enrolled by participating researchers from spanish hospitals that have a pediatric surgery service, in addition to surgery on adult patients, who will collect and upload the data into a protected web-based electronic database. the recorded variables are grouped as follows: patient variables, hospital data, data prior to cardiopulmonary arrest (crp), data from cardiopulmonary arrest (crp), data after cardiopulmonary resuscitation (cpr), results of cardiopulmonary resuscitation (cpr). for the study, cardiorespiratory arrest (crp) is defined as cardiac arrest for which resuscitation is attempted with chest compressions, defibrillation, or both. in the pediatric population it may include patients receiving chest compressions for poor perfusion in the setting of severe bradycardia. the inclusion criteria are: all patients older than 1 month who undergo sedation, anesthesia or monitored anesthetic surveillance performed by an anesthesiologist and suffer cardiorespiratory arrest in the surgical block. subsequent episodes of cardiorespiratory arrest (crp) in the same subject may be included. exclusion criteria: hospitals that do not have a pediatric surgery service in their service portfolio, patients being treated with extracorporeal circulatory support (ecmo, extracorporeal circulation pump or ventricular assistance) at the time of cardiorespiratory arrest. patients who suffer cardiac arrest and require any type of extracorporeal circulatory support for the recovery of spontaneous circulation after performing the corresponding cardiopulmonary resuscitation (cpr) will not be eliminated. the data collection period will be valid for 48 months, starting on june 1, 2025 and the last day being june 1, 2029.

Eligibility criteria:
inclusion criteria:patients over 1 month of age who suffer cardiac arrest in the surgical unit and/or in those places where some type of monitored surveillance technique, sedation and/or anesthesia is performed by an anesthesiologist or internal resident specialist (eir) of the specialty of anesthesiology. exclusion criteria: * patients with procedures defined as major outpatient surgery in the hospital where the cardiac arrest occurs. * patients in supportive treatment extracorporeal circulatory system (ecmo) or ventricular assist at the time of cardiac arrest.
hematologic toxicity observation of the docetaxel+ cisplatin+ fluorouracil (tpf)medical protocol

Conditions: Squamous Cell Head and Neck Carcinoma

Summary: the ending of this study is to describe the effect of febrile neutropenia on patients who receive a chemotherapy by docetaxel+cisplatin+fluorouracil(tpf).

in this study we will describe * habits of medical staff in prescription of growth factors or antibiotic prophylaxis * ratio of patients treated by growth factors in primary or secondary prophylaxis * ratio of patients treated in primary prophylaxis who present a febrile neutropenia * ratio of patients who need to be hospitalized and the duration of those hospitalizations. * causes of lateness, of decreasing, and of stop of chemotherapy * antibiotic and growth factors prophylaxis tolerance .

Eligibility criteria:
inclusion criteria: * patients with histologically proved head and neck squamous cell carcinoma * age: more than 18 * patients who are beginning a chemotherapy (docetaxel+cisplatin+ 5fu) * patients must have been informed of automatic data processing concerning them. exclusion criteria: * previous chemotherapy for the head and neck squamous cell carcinoma * previous chemotherapy for an other cancer in the two years before * intercurrent illness that could significantly interfere with chemotherapy such as hiv infection, infection or active febrile illness, a chronic intestinal disease

Keywords: effect of febrile neutropenia resulting chemotherapy by tpf
a study for improving the outcome of childhood acute promyeloid leukemia

Conditions: Childhood Acute Promyelocytic Leukemia

Summary: outcome of acute promyelocytic leukemia (apl) has greatly improved since the introduction of all-trans-retinoic acid (atra). treatment with atra and anthracycline-based chemotherapy (atra + chemotherapy) decreases relapses of the disease as well as early hemorrhagic deaths. nowadays patients with apl have an event-free survival (efs) of up to 80%. however, there remains a subset of the patients in whom the disease relapses. recently, a randomized prospective study showed that the addition of ato to "atra + chemotherapy" treatment protocol had a significantly higher efs in patients with apl than those treated with "atra + chemotherapy" protocol. the patients treated with "ato + atra + chemotherapy" had a five years efs of 89.2%. moreover, a recent study showed that indigo naturalis formula (rif), a traditional chinese medicine with tetraarsenic tetrasulfide (as4s4), indirubin, and tanshinone iia as major active ingredients, yielded synergy in the treatment of a murine apl model in vivo and in the induction of apl cell differentiation in vitro . it is about 20 years since rif was used to treat alp in china. clinical studies showed that this agent was effective against apl. compared to ato, rif is relatively inexpensive and can be taken orally, resulting in reducing the number of hospital days and the treatment cost. however, there is no report comparing treatment outcomes of "ato + atra + chemotherapy" and "rif + atra + chemotherapy" protocols in children with apl so far. for this purpose, therefore, investigators are going to conduct a multicenter and randomized prospective study in children with apl.

objectives: * determine the safety and efficacy of "ato/rif + atra + less intensive chemotherapy" protocol in children with acute promyelocytic leukemia (apl). * compare the safety，efficacy and treatment cost of "rif + atra + less intensive chemotherapy" with "ato + atra + less intensive chemotherapy" protocol in children with apl. determine if ato can be substituted by rif. outline: this is a multicenter and randomized prospective study. projected accrual: a total of 162 patients will be accrued for this study.

Eligibility criteria:
inclusion criteria: * patients less than 16 years old with newly diagnosed pml-rara positive acute promyelocytic leukemia. exclusion criteria: * patients who have coma, convulsion or paralysis due to intracranial hemorrhage or central nervous system leukemia at diagnosis.
the impact of patient involvement in decision-making about heart disease prevention

Conditions: Cardiovascular Disease

Summary: the purpose of this study is to determine whether providing patients with information about their global coronary heart disease (chd) risk and effective risk-reducing strategies allows them to make appropriate decisions about heart disease prevention.

background: low utilization of effective chd prevention strategies may be due to many factors, but chief among them is the lack of patient involvement in prevention decisions. we undertook this study to test the effectiveness of an individually-tailored, computerized decision aid about chd on patients' discussions with their doctor and their plans for chd prevention. methods: we conducted a pilot randomized trial in a convenience sample of adults with no previous history of cardiovascular disease to test the effectiveness of an individually-tailored, computerized decision aid about chd prevention against a risk factor list that patients could present to their doctor.

Eligibility criteria:
inclusion criteria: * presenting for routine medical care with regular medical provider * able to understand, speak, and read english exclusion criteria: * prior history of cardiovascular disease * history of serious medical illness that would limit candidacy for screening * previous participation in intensive risk modification as part of diabetes study in our clinic * no cholesterol measurement in the last 3 years, limiting ability to provide up-to-date risk estimate

Keywords: risk assessment decision support technique physician-patient relations prevention and control
bami. the effect of intracoronary reinfusion of bone marrow-derived mononuclear cells(bm-mnc) on all cause mortality in acute myocardial infarction

Conditions: Myocardial Infarction; Death

Summary: this is a multinational, multicentre, randomised open-label, controlled, parallel-group phase iii study. its aim is to demonstrate that a single intracoronary infusion of autologous bone marrow-derived mononuclear cells is safe and reduces all-cause mortality in patients with reduced left ventricular ejection fraction(\</=45%) after successful reperfusion for acute myocardial infarction when compared to a control group of patients undergoing best medical care.


Eligibility criteria:
inclusion criteria: * signed and dated informed consent form * men and women of any ethnic origin aged≥18years * patients with acute st-elevation myocardial infarction as defined by the universal definition of ami (including new lbbb) * patients with acute st-elevation myocardial infarction as defined by the universal definition of ami. * successful acute reperfusion therapy (residual stenosis visually \<50% and timi flow ≥2) within 24 hours of symptom onset or thrombolysis within 12 hours of symptom onset followed by successful percutaneous coronary intervention (pci) within 24 hours after thrombolysis * left ventricular ejection fraction ≤ 45% with significant regional wall motion abnormality assessed by quantitative echocardiography (central, independent core lab analysis) 2 to 6 days after reperfusion therapy * open coronary artery suitable for cell infusion supplying the target area of abnormal wall motion exclusion criteria: * participation in another clinical trial within 30 days prior randomisation unless non interventional trials or trials where patients are randomised to only standard care and this has been discussed and agreed with the ci/sponsor prior to consenting * previously received stem/progenitor cell therapy * pregnant or nursing women * mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study or to follow the protocol * necessity to revascularise additional vessels, outside the target coronary artery at the time of progenitor cell infusion (additional revascularisations after primary pci and before bm-mnc cell infusion are allowed), unless clinically indicated and according to latest guidelines. this decision should be made at the time of the index procedure and explicitly stated at that time. * cardiogenic shock requiring mechanical support * platelet count \<100.000/µl, or hemoglobin \<8.5 g/dl * impaired renal function, i.e. creatinine \>2.5 mg/dl * fever or diarrhoea not responsive to treatment within 4 weeks prior screening * cliinically significant bleeding disorder within 3 months prior screening * uncontrolled hypertension (systolic \>180 mmhg and diastolic \>120 mmhg) * life expectancy of less than two years from any non-cardiac cause or uncontrolled neoplastic disease

Keywords: stem cells acute myocardial infarction heart failure heart attack bone marrow intracoronary reinfusion bone marrow derived mononuclear cells left ventricular function improvement mortality
extend iii - efficacy and safety of ranibizumab in patients with subfoveal choroidal neovascularization (cnv) secondary to age-related macular degeneration (amd)

Conditions: Choroidal Neovascularization; Age-Related Macular Degeneration

Summary: this study will evaluate efficacy and safety for monthly ranibizumab 0.5 mg intravitreal injections in asian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.


Eligibility criteria:
inclusion criteria: * male or female asian patients 50 years of age or greater. * patients with primary or recurrent subfoveal cnv secondary to amd, including those with predominantly classic, minimally classic or active occult lesions with no classic component. * patients who have a bcva score between 73 and 24 letters (approximately 20/40 to 20/320 snellen equivalent), inclusively, in the study eye. * total area of cnv (including both classic and occult components) encompassed within the lesion must be \>= 50% of the total lesion area * total lesion area must be \<= 12 disc areas exclusion criteria: * patients who have in the fellow eye a snellen equivalent below 20/200 * presence of angioid streaks, presumed ocular histoplasmosis syndrome, myopia (exceeding -8 diopters), or cnv secondary to causes other than amd in the study eye * subfoveal fibrosis or atrophy in the study eye * total area of cnv (including both classic and occult components) encompassed within the lesion must be \>= 50% of the total lesion area * total lesion area must be \<= 12 disc areas * vitreous hemorrhage, retinal tear or history of rhegmatogenous retinal detachment or macular hole (stage 3 or 4) in the study eye. * active, or history of, ocular inflammation or infection in the study eye within the last 30 days prior to screening. * uncontrolled glaucoma in the study eye * treatment in the study eye with verteporfin, external-beam radiation therapy, subfoveal focal laser photocoagulation, vitrectomy, submacular surgery, or transpupillary thermotherapy within 30 days prior to screening * previous treatment with anti-angiogenic drugs (pegaptanib, ranibizumab, bevacizumab, anecortave acetate, corticosteroids, protein kinase c inhibitors, squalamine, sirna, vegf-trap etc.) for neovascular amd in the study eye. treatment of the fellow eye is permitted if administered \> 30 days before screening. * history of intraocular surgery in the study eye including pars plana vitrectomy, except for uncomplicated cataract surgery more than 60 days prior to screening * history of yag laser posterior capsulotomy in the study eye within 30 days prior to screening

Keywords: age-related macular degeneration amd ranibizumab anti-vegf choroidal neovascularization cnv asian patients korea taiwan associated
improving continuous renal replacement therapy outcomes in neonates and infants through interdisciplinary collaboration

Conditions: Acute Kidney Injury; Chronic Kidney Diseases; Renal Dialysis

Summary: to date, little knowledge exists related to the use of hemodialysis (hd) in infants and has been limited to mainly single center studies. the carpediem (cardio-renal pediatric dialysis emergency machine) device, which can be used to provide hemodialysis in infants, has been launched in the united states. this study/registry is designed to obtain data on critically ill infants who require hd using the carpediem device to understand the indications for initiation, best practice in prescribing and performing treatment, expected treatment course, and outcomes of a dedicated infant continuous renal replacement therapy (crrt) machine.

this is a retrospective and prospective, multicenter observational quality improvement study and research registry. infants undergoing renal replacement therapy utilizing carpediem for hemodialysis will be enrolled in the study for observation. there are two arms to this study, one for quality improvement and one for research purposes. patients enrolled in this study have the option to participate additionally in either biospecimen collection, long term follow up after carpediem, or both. urine specimen will be collected from fresh voids, but all blood specimen will be obtained from residual clinical specimen. investigators hope to gain more information into use, treatment course, and outcomes from infants requiring treatment with the carpediem device.

Eligibility criteria:
inclusion criteria: * treated with carpediem as part of standard of care at a participating institution within the united states exclusion criteria: * parents/legally authorized representative unable or unwilling to provide consent
"equistasi" and gait in hemiparesis

Conditions: Hemiparesis

Summary: the purpose of the study is to evaluate the effect of "equistasi" device on quantitative and qualitative gait characteristics in patients affected by hemiparesis.


Eligibility criteria:
inclusion criteria: * subacute hemiparesis * functional ambulation classification \<4 exclusion criteria: * previous neurological deficits * glasgow coma scale \<13 * complete sensory deficit in the lower limbs * levels of cognitive functioning ≤5 * polyneuropathy * contraindications to mobilization/verticalization
a trial of photodynamic therapy with hpph for treatment of dysplasia, carcinoma in situ and t1 carcinoma of the oral cavity and/or oropharynx

Conditions: Dysplasia; Carcinoma of the Oral Cavity; Carcinoma of the Oropharynx

Summary: recent literature suggests that certain patients with squamous cell cancers of the head and neck region may benefit from photodynamic therapy whether or not they may have received prior therapy, e.g. radiation therapy

we propose to initiate a phase 1 a clinical trial using hpph and 665 nm light in patients with cancer of the oral cavity and/or oropharynx, including lesions of moderate to severe dysplasia, squamous carcinoma in situ and t1 squamous cells carcinoma. the study will employ a fixed hpph dose of 4 mg/m2 infused over 1 hour, and 24 hours later light doses escalating from 100 j/cm2 to 125 and 140 j/cm2, respectively. the primary goal is the determination of the maximally tolerated pdt dose. preliminary evidence for pdt efficacy wil also be obtained.

Eligibility criteria:
inclusion criteria: * patients with moderate to severe dysplasia and/or squamous carcinoma-in-situ of the oral cavity and/or oropharynx. * patients with t1 squamous cell carcinoma of the oral cavity and/or oropharynx. * patient may have primary and/or recurrent lesions to be treated. * diagnosis must confirmed by biopsy. * prior therapy of any type is allowed. * male or female patients at least 18 years old. female patients must not be pregnant and must be practicing a medically acceptable form of birth control, be sterile or post-menopausal. male patients should be using a medically acceptable form of birth control or be sterile. * patients must have an ecog score of 0-2 (appendix a 1 ). * patient or legal representative must understand the investigational nature of this study and sign an independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure. exclusion criteria: * patients with t2 or greater squamous cell carcinoma. * true tongue base lesions (as determined by the treating physician). * patients with severe trismus that prevents adequate access to the lesion for treatment light delivery (as determined by the treating physician). * porphyria or hypersensitivity to porphyrin or porphyrin-like compounds. * patients with impaired hepatic (alkaline phosphatase (hepatic) or sgot;:3 times the upper normal limits). * patients with minimal impairment of renal function (total serum bilirubin;: 2 mg/dl, serum creatinine;: 2 mg/dl) * unwilling or unable to follow protocol requirements. * any condition which in the investigator's opinion deems the patient an unsuitable candidate to receive study drug and or light treatment. * patients on concurrent chemotherapy or radiation therapy or less than 4 weeks after the last dose of chemotherapy or radiation therapy. inclusion of women and minorities: * both men and women and members of all races and ethnic groups are eligible for this study.

Keywords: photodynamic therapy oral dysplasia oral cavity carcinoma oropharynx carcinoma.
natural history study of patients with limb-girdle muscular dystrophy 2i

Conditions: LGMD2I

Summary: prospective, longitudinal, interventional, single-group, multicenter natural history study to better know the lgmd2i disease physiopathology. the duration of participation for each patient will be up to 24 months.

study duration duration from first visit of first patient (fpfv) to last visit of last patient (lplv) : 3 years study objectives primary objective: to characterize the disease course in limb-girdle muscular dystrophy 2i (lgmd2i) patients using standardized and disease appropriate evaluations. secondary objectives: to identify clinical, imaging and/or laboratory parameters that are indicators of the disease course in lgmd2i to identify the best outcome measure for further therapeutics approaches

Eligibility criteria:
inclusion criteria: 1. female and male patients 2. patients ≥ 16 years old 3. clinical diagnosis of lgmd2i and gene testing demonstrating two pathogenic mutations in fukutin-related protein gene, fkrp) 4. ambulant patients exclusion criteria: 1. patients presenting other disease which may significantly interfere with the interpretation of lgmd2i natural history
the coherex flatstent™ ef pfo migraine registry

Conditions: Patients With Migraine and PFO

Summary: a prospective, single arm, multicenter clinical registry evaluating the change in migraine headaches in migraine with aura patients who undergo patent foramen ovale (pfo) closure with the coherex flatstent™ ef pfo closure system.


Eligibility criteria:
major inclusion criteria: age 18-65 males and non pregnant females history of refractory migraine documented pfo major exclusion criteria: known allergy to aspirin or nickel. medication overuse headache body mass index \> 40. recent botulinum neurotoxin type a treatment other known structural heart disease, coronary artery disease, atrial fibrillation pfo morphology not suitable for flatstent ef patients who have had a stroke within the past two months post-traumatic headache. patients with diagnosed hypercoagulable states that require chronic treatment with warfarin.

Keywords: migraine
modifying diet to improve gut microbiome

Conditions: Obesity

Summary: the investigators will conduct a 2-arm randomized controlled pilot, feasibility feeding study in which 28 participants will be randomized to receive either a calorie-restricted dietary approaches to stop hypertension (dash) diet or a calorie-restricted standard american diet provided by the study for 4 weeks. participants will be non-hispanic black or white, generally healthy females (14 black, 14 white). the investigators will collect fecal samples at multiple time points before, during, and after the dietary intervention to analyze for changes in the gut microbiota and functional-level metabolic products. this work will be led by an interdisciplinary team including expertise in bio-behavioral science, microbiology, nutrition science, bioinformatics, and biostatistics all with cross-cutting expertise in health disparities, prevention research, nutrition, the gut microbiota, inflammation and other biomarkers. the rationale for the proposed research is that once the interactions between race, diet, and the gut microbiota are more fully understood, targeted diet modifications may provide new and innovative approaches for the prevention and treatment of obesity and obesity-related diseases.


Eligibility criteria:
inclusion criteria: * female * non-hispanic, black or white * age 19-65 years * bmi \>= 30 kg/m\^2 * able to visit bionutrition unit daily exclusion criteria: * gastrointestinal (gi) conditions i.e., irritable bowel, diverticulitis, peptic ulcers, crohn's, gi cancers, and adenatomous polyps * antibiotic or probiotic use in the previous 90 days * tobacco use * heavy alcohol consumption * major medical conditions (e.g., renal disease, diabetes, cancer)